University of Arizona Researchers Develop Long-Acting Opioid Overdose Reversal Agent
Key Insights
University of Arizona researchers have identified a new molecule that could reverse opioid overdoses with longer-lasting effects than naloxone, potentially requiring only a single dose.
The experimental treatment addresses naloxone's 30-minute duration limitation and may be more effective against carfentanil, a synthetic opioid 100 times stronger than fentanyl.
Researchers aim to make the drug widely available within one to two years through expedited FDA approval, targeting Arizona's crisis where over five people die daily from opioid overdoses.
Researchers at the University of Arizona have identified a breakthrough molecule that could revolutionize opioid overdose (search) treatment by providing longer-lasting reversal effects than current standard therapy. The discovery addresses critical limitations of naloxone (Narcan), which requires multiple doses due to its brief 30-minute duration of action.
Todd Vanderah, Director of the Comprehensive Center for Pain and Addiction at the University of Arizona and lead researcher on the study, explained the fundamental problem with existing treatment: "The problem is that one dose lasts 30 minutes, [and] often a person may wake up from the overdose. If they have a large amount of fentanyl on board or an opiate, they can go back into that opiate-comatose or something or even die."
Enhanced Efficacy Against Synthetic Opioids
The newly discovered molecule demonstrates particular promise against carfentanil, a synthetic opioid that is 100 times stronger than fentanyl. Vanderah indicated that the experimental treatment is expected to be more effective than naloxone against this potent synthetic compound, which has proven challenging for current overdose reversal protocols.
Beyond improved potency, the new molecule may address wooden chest syndrome (search), a dangerous condition that causes abdominal muscles to tense during overdose, complicating resuscitation efforts. "We're hoping, because we're in early stages, trying to determine whether it won't produce or actually reverse the wooden chest syndrome," Vanderah said.
Addressing Arizona's Overdose Crisis
The development comes as Arizona faces a severe opioid crisis, with more than five people dying from opioid overdoses daily according to the Arizona Department of Health Services (search). In Pima County specifically, drug deaths have reached unprecedented levels since 2017.
Mark Person, Public Health Program Manager for the Pima County Health Department (search), described the escalating situation: "We saw annual numbers hit 400, 500 deaths in a year which is really unheard of." He noted that 40-50% of these deaths involve opioids, with fentanyl being the most common cause.
"When we talk about drug deaths, opioids is a huge driver of this crisis," Person emphasized, highlighting the urgent need for improved treatment options.
Clinical Development Timeline
The research team is pursuing an accelerated development pathway, aiming to make the drug widely available within one to two years. Vanderah outlined their regulatory strategy: "We're hoping that we can kind of get an expedient approval through the FDA, and get an IND, and get it into humans quickly."
The single-dose requirement could significantly benefit first responders, who typically carry limited naloxone supplies. This logistical advantage, combined with extended duration of action, could reduce the need for repeated administrations that currently characterize overdose response protocols.
Community Impact and Future Implications
The potential impact extends beyond clinical efficacy to community-level overdose prevention efforts. Dezi Rachels, president of Team Awareness Combatting Overdose (TACO) at the University of Arizona, who lost her best friend to an opioid overdose (search), expressed optimism about the development: "The fact that these could be available to save lives soon is just awesome, you know, those are more lives saved which is always a good thing."
Despite a spike in overdose deaths in January of this year in Pima County, Person indicated that year-end numbers are expected to be lower than 2024 figures, suggesting some progress in addressing the crisis while highlighting the continued need for improved therapeutic interventions.